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REVIEW CURRENTOPINION Progress in genetic association studies of
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This review summarizes recently published large-scale efforts elucidating the genetic architecture of lipid
levels. A supplemental file with all genetic loci is provided for research purposes and we performed
bioinformatic analyses of the genetic variants to give an oversight of involved pathways.
Recent findings
In total, 52 genes for HDL cholesterol, 42 genes for LDL cholesterol, 59 genes for total cholesterol, and
39 genes for triglycerides have been identified. Genetic overlap is present between the different traits and
similar pathways are involved. Most of the SNPs that were detected in the European studies could be
replicated in other ethnicities and these SNPs show the same direction of effect suggesting that the
underlying genetic architecture of blood lipids is similar between ethnicities.
Summary
Genetic studies have identified many loci associated with plasma lipids and have provided insight into the
underlying mechanisms of lipid homeostasis. Future research is needed to determine whether these loci
may be novel targets for lipid-lowering therapy and for reducing cardiovascular disease risk. In addition,
the proportion of genetic variance explained by these lipid loci is still limited and new large-scale genetic
studies are ongoing to identify additional common and rare variants associated with lipid levels.
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LDL cholesterol (LDLc), total cholesterol (TC), and
triglycerides are heritable risk factors for cardiovas-
cular disease. The heritability estimates range from
0.28 to 0.78 in twin and family studies for the
different lipid traits [1] suggesting that lipid levels
are, at least partially, genetically determined and
that genetic information can be used for early pre-
diction of deviations from mean levels. Currently,
the field of complex genetics is moving fast and it is
hard to keep up-to-date with the literature reporting
novel genetic associations. An overview of all var-
iants found in genome-wide association studies
(GWASs) is given, and updated regularly, on the
website www.genome.gov/gwasstudies, but this
resource is only reporting on findings from GWASs.
Newer targeted genotyping platforms, such as the
candidate-gene ITMAT-Broad-CARe (IBC) array
(Illumina, San Diego, California, USA), Metabochip
array, and exome chip array, developed to further
refine the GWAS signals, are not covered by this
catalogue. This review will summarize large-scale
genetic studies using different types of arraysilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkof loci associated with the different lipid traits. A
supplemental file with all loci is provided for
research purposes, as investigators may want to
perform look-ups in other cohorts to search for
pleiotropic effects of the different genes. Finally,
we performed bioinformatic analyses of the lipid
loci to identify pathways likely to be relevant to
these traits.thorized reproduction of this article is prohibited.
ins www.co-lipidology.com
CKEY POINTS
 Genetic studies have successfully identified a large
number of lipid loci including multiple potential novel
targets for drug development.
 The underlying genetic architecture of blood lipids is,
for a large part, similar between ethnicities, but
population-specific lipid loci have been identified.
 Efforts are ongoing to identify rare variants and
additional common variants to explain a larger
proportion of the genetic variance in
diverse populations.
 Functional follow-up studies of novel lipid loci and
studies investigating the relation of novel loci to
cardiovascular outcome are crucial to further elucidate
the underlying biology and drug target validation.
Genetics and molecular biologyGENOME-WIDE ASSOCIATION STUDIES
As reviewed previously in this Journal [2], a large
GWAS meta-analysis from the Global Lipids Con-
sortium (GLGC) with more than 100000 samples
has identified 95 known and novel genetic loci
associatedwith lipid levels [3]. These loci are all listed
in Supplemental Table 1, http://links.lww.com/COL/
A4. This study clearly shows the clinical relevance of
performing GWASs. For example, a common genetic
variant in the HMGCR locus was found to be signifi-
cantly related to LDLc. More importantly, this locus
was also related to coronary artery disease (CAD) in
line with the well established effect of statins, which
inhibit HMGCR (3-hydroxy-3-methylglutaryl CoA
reductase). Interestingly, this GWAS identified genes
that harbor pathogenic mutations causing familial
hypercholesterolemia, such as the LDLR and PCSK9
genes, both ofwhichwere also found to be associated
with CAD [3].ITMAT-BROAD-CARE CARDIOCHIP
Recently, the International IBC Lipid Genetics Con-
sortium [4
&&
], using the gene-centric IBC chip cover-
ing approximately 50000 DNA markers across 2000
genes previously implicated with cardiovascular dis-
ease, performed a meta-analysis involving genetic
data from over 65000 individuals and replicated the
results in an independent set of studies with over
25000 individuals of European ancestry and the
GLGC results [3]. This study identified 21 novel
genes associated with levels of LDLc, HDLc, TC,
and triglycerides. Some of the new loci reported
were found in interesting and unexpected loci, such
as the BMI locus FTO [5], suggesting a causal
relationship between adiposity and HDLc, as this
relation became nonsignificant when introducingopyright © Lippincott Williams & Wilkins. Unautho
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breast cancer susceptibility locus BRCA2 [6] was
associated with LDLc, but the underlying mechan-
ism responsible for this association is not yet
understood. Future studies are needed to fully com-
prehend the involved pathways and whether these
loci may be potential targets for drug treatment.
Other detected loci may become clinically relevant
in the short-term such as the INSR gene, which was
previously associated with triglyceride levels in
animal models [7]. Berberine, an isoquinoline
alkaloid found in the root, rhizome, and stem bark
of many plant species and used as a traditional
Chinese medicine, is believed to upregulate the
expression of INSR through the protein kinase
C-dependent pathway [8] and has been associated
with lowering of fasting blood glucose, insulin, and
triglyceride levels in a clinical study of type 2 dia-
betes patients, confirming the relationship between
the insulin receptor and triglyceride levels [9].
Another identified drug target is the HCAR2 gene,
which was related to HDLc. HCAR2 is also known as
niacin receptor 1, a well known target of niacin.
Niacin has been shown to lower LDLc levels and
increase HDLc [10]. Niacin treatment led to
regression of carotid intima–media thickness in
patients with an LDLc less than 2.6mmol/l included
in the Arterial Biology for the Investigation of the
Treatment Effects of Reducing Cholesterol 6-HDL
and LDL Treatment Strategies in Atherosclerosis
(ARBITER-6-HALTS trial) [11]. Despite their larger
effects, the Intervention in Metabolic Syndrome
with LowHDL/High Triglycerides: Impact onGlobal
Health Outcomes (AIM-HIGH) study, however, did
not demonstrate any significant effect on outcome
in patients with LDLc less than 1.8mmol/l during a
mean follow-up of 3 years, despite improvements in
HDLc [12]. Niacin lowers LDLc in part through
inhibition of DGAT2, another significant locus in
the IBC meta-analysis. DGAT2 is also the presumed
target of Omacor (Lovaza), a drug on the market for
treatment of hypertriglyceridemia [13]. Future
studies are necessary to investigate the pleiotropic
effects of the detected novel lipid loci from the IBC
Cardiochip and assess their relationship with
relevant cardiovascular outcomes.
The International IBC Lipid Genetics Consor-
tium was also able to verify 49 of the 136 GLGC
reported associations, which due to lack of a large
enough independent sample were not previously
replicated. Another 38 loci in the GLGC were not
represented in the IBC chip showing some of the
shortcomings of gene-centric approaches. The
researchers also found that some of the strongest
signals appeared to have sex-specific effects but in
none of the loci was the effect solely present in arized reproduction of this article is prohibited.
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Genetic association studies of plasma lipids Asselbergs et al.single sex. Based on the denser coverage provided by
the IBC chip compared to GWAS arrays, it was
revealed that a number of well known loci have
a much more complex genetic architecture than
previously thought. Almost one in five of all the
genotyped SNPs in the study were of frequency
lower than 1%, but half of all the statistically
significant signals belonged in this category. Of note
was the very strong association seen between
the familial hypercholesterolemia causing APOB
R3527Q (rs5742904) and LDLc (P¼1.0391046).
This, along with the great majority of the associ-
ations identified with rare variants, was not pursued
further due to the restriction imposed on the results
in terms of themeta-analysis heterogeneity measure
of I2, which for rs5742904 was 96.6%.
Interestingly, the IBC study further supported
that the heritability of lipids, based on the additive
effects of SNPs, differs among sexes with women
having higher heritability for HDLc but potentially
lower heritability for triglycerides compared to
men, whereas no difference could be found for
LDLc and TC [4
&&
,14]. However, so far we can
still only explain less than a third of the expected
genetic heritability of lipid levels, around 10–15%
[4
&&
]. It is currently believed that a large proportion
of this heritability is explained by common var-
iants, as illustrated by Vattikuti et al. [15
&
] who
showed that 58% of the genetic variance of height
could be explained by considering all common
SNPs. We expect that the explained heritability
of lipids will increase as more common functional
variants are identified by ongoing initiatives such
as the 1000 genomes imputed meta-analysis and
specific targeted arrays such as the Metabochip. It
has also been speculated that the remaining pro-
portion of the heritability may be explained by rare
variants [minor allele frequency (MAF)<5%] [16].
However, despite their larger effects, uncommon
variants, such as those found in the PCSK9 [17] and
LDLR [18] genes, may not contribute significantly
to the problem of ‘missing’ heritability. A recent
study by Park et al. [19
&
] showed that common SNPs
explain a larger fraction of the genetic variance
than genetic variants with a lower allele frequency.
However, this study did not investigate the contri-
bution of variants with an allele frequency less
than 1%.BIOINFORMATICS ANALYSES
We conducted a bioinformatic analysis of the gene
loci identified by the GLGC and IBC consortia. We
included the genes listed by the authors, as shown in
Supplemental Table S1, http://links.lww.com/COL/
A4, as well as several of the genes around the topCopyright © Lippincott Williams & Wilkins. Unau
0957-9672  2013 Wolters Kluwer Health | Lippincott Williams & WilkSNPs, when in an area of dense gene clusters.
The Mouse Genome Informatics functional enrich-
ment tool VLAD (http://proto.informatics.jax.org/
prototypes/vlad-1.0.3/) was used to look for over-
representation of Gene Ontology biological proc-
esses represented by each gene list dataset relative to
the human dataset as a whole. The goa_human
annotation set was selected; the query dataset (as
UniProt IDs) was pasted into the ‘Query Set’ field.
The ‘Universe Set’ field was left blank (to specify all
human genes in annotation file). The ‘Display
Settings’ options selected were ‘Pruning threshold’:
3 and ‘Collapsing threshold’: 6. A graphical sum-
mary of the functional analyses is shown in Fig. 1,
and the more detailed outputs of these analyses can
be found in Supplementary Tables S2–S5, http://
links.lww.com/COL/A4. Tables S6, http://links.
lww.com/COL/A5 and S7, summarize the functional
analyses results obtained. Not surprisingly, some
overlap exists between the genetic architecture of
the different lipid traits as illustrated in Fig. 1. Most
pathways are shared by all four traits and only a few,
such as ‘digestion’, are present in a selection.
Although all traits are associated with the ‘circula-
tory system development’ category, LDLc has the
largest number of genes in this group. From Fig. 1, it
is also evident that the four main roles of lipids in
the body are represented in almost similar percen-
tages, though ‘metabolism’ is the most common
category and ‘coagulation’ is only represented in
HDLc. The overlap of the processes is not surprising
when Fig. 2 and Supplemental Table S1, http://links.
lww.com/COL/A4 are considered. Six genes are
associated with all fours traits, CETP, APOB,
FADS1-2-3, APOE, APOA1, and TRIB1, although
not always with the same SNP. HDLc is the trait
with the largest number of unique associations, 28,
whereas LDLc and TC seem to have the largest
overlap with 25 genes in common. Finally, although
TC is the lipid trait with the largest number of
associated genes, 59, there are only five unique
signals verifying its role as a grouping measure of
the lipid profile.ONGOING EFFORTS: METABOCHIP,
EXOME CHIP, AND SEQUENCING
Recently, a number of efforts to further investigate
the identified lipid signals have been made public.
The Metabochip array of nearly 200000 SNP
markers aims to follow up the most significant
associated variants from the GWAS meta-analysis
on type 2 diabetes, CAD and myocardial infarction,
and quantitative traits related to these diseases, in
order to find additional variants and refine previous
associations through fine mapping [20]. For lipids,thorized reproduction of this article is prohibited.
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FIGURE 1. Diagrammatic representation of the enrichment of Gene Ontology terms within the genes associated with lipid trait
SNPs. A selection of the enriched Gene Ontology terms are listed on the outer arc (full list of enriched Gene Ontology terms in
Supplemental Table S7, http://links.lww.com/COL/A4). The inner arc provides biological process grouping terms for the
Gene Ontology terms on the outer arc. The arcs represent the percentage of genes in all four lipid trait datasets, which are
annotated to these Gene Ontology terms.
Genetics and molecular biology65345 SNPs with preliminary evidence for associ-
ation were meta-analyzed with the previous GWAS
results in a total sample size of up to 188578 indi-
viduals. Lipid levels were associated with 167
genomic regions, of which 63 were novel. These
novel signals were in pathways with other, pre-
viously known, lipid-related genes. Loci associated
with HDLc, LDLc, TC, and triglycerides were also
associated with other cardiovascular and metabolic
traits such as T2D, CAD, BMI, and blood pressure
[21]. Other ongoing efforts include the work by
the European Network for Genetic and Genomic
Epidemiology (ENGAGE) consortium [22], which
uses 1000 Genomes imputed GWAS data and pre-
liminary results suggest that another 19 novel
associations can be identified by this approach.
The increasing affordability of whole genome
sequencing has made the sequencing of patients
with high lipid levels and their comparison with
individuals of normal or low lipid levels possible.opyright © Lippincott Williams & Wilkins. Unautho
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loci, but also to fine map already established loci.
It is likely that these efforts will be able to extend
our ability to detect new rare variants with high
effect sizes, although those with more moderate
effects will require increasingly bigger sample
sizes. As an example of this approach, a recent
study by Sanna et al. [23] sequenced the PCSK9 and
LDLR genes and detected several rare variants that
were missed by conventional GWASs. The costs of
performing whole exome and whole genome
sequencing in individuals has dropped dramatic-
ally, but still it remains unaffordable to sequence
complete genomes in large populations. As
an intermediate solution, both Affymetrix and
Illumina have developed an exome array contain-
ing variants in coding regions that have been seen
more than once in existing whole genome or
whole exome sequence datasets. Detailed descrip-
tion of the design of the exome chip can berized reproduction of this article is prohibited.
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FIGURE 2. Venn diagram showing the overlap between the
genes associated with the four lipids traits from large-scale
studies up to now.
Genetic association studies of plasma lipids Asselbergs et al.found on http://genome.sph.umich.edu/wiki/
Exome_Chip_Design. The first results of the exome
chip on lipid traits are expected soon.MULTIETHNIC ANALYSES
Genetic studies have predominantly been per-
formed in individuals with European ancestry. How-
ever, most of the SNPs that have been detected in
European studies have also been replicated in other
ethnicities. The Global Lipid Consortium has vali-
dated their identified SNPs in several non-European
populations including African–Americans, East
Asians, and South Asians [3]. In addition, most of
these SNPs show the same direction of effect,
suggesting that the underlying genetic architecture
of blood lipids is similar between ethnicities. How-
ever, some of the associated loci seem to be unique
for a specific ethnic background. For example, a
recent meta-analysis in approximately 10000 indi-
viduals from different ethnicities (e.g., Hispanic,
African–American, East Asian) using the previously
mentioned IBC Cardiochip found a significant
association betweenHDLc and a nonsensemutation
within the CD36 locus in the African–American
population [24
&
]. This variant, rs3211938-G, hasCopyright © Lippincott Williams & Wilkins. Unau
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with CD36 deficiency and with susceptibility to
malaria [25] and is nearly absent in Europeans, with
a MAF of 0.0005, suggesting a population-specific
variation.
Additional studies are ongoing to further inves-
tigate the contribution of rare variants in other
ethnicities. Recently, whole exome data for 3581
individuals from different ethnicities suggested an
association between titin (TTN) and HDLc, and
between thymocyte nuclear protein 1 (THYN1)
and cholesterol [26]. However, these results are still
pending replication in independent studies.IDENTIFICATION OF CAUSAL VARIANTS
It is important to realize that the identified genetic
variant is not per se responsible for the association
with the lipid trait, as most often they are tagging
the functional change which might be located out-
side the gene or in a different gene altogether.
Attention is now focusing on the identification of
these causal variants using statistical and laboratory
approaches. The recently published Encyclopedia
Of DNA Elements (ENCODE) data may play an
important role in identifying functional regulatory
regions of the genome involved in lipidmetabolism,
with a number of relevant cell lines included [27
&&
].
A recent study examined the effect of variation upon
open chromatin and was able to identify a causal
regulatory variant for HDLc levels within the gene
encoding LXR-a (rs7120118) [28]. This study high-
lighted the problems of GWASs, as linkage disequi-
librium at this region spansmore than 29 genes, and
the lead SNP was previously assigned to F2, a gene
involved in clotting [3]. Novel use of statistical
methods can be applied to fine-mapping studies,
and a recent Bayesian approach has been applied to
identify causal variants for coronary heart disease
(CHD) and T2D [29], a method that could equally be
applied to lipid traits. A study of functional variants
at the LPL locus combined both statistical and
laboratory methodologies to identify two independ-
ent regulatory variants (rs327 and rs3289) [30]
associated with triglyceride levels, in addition to
the established rs328 (S447X) variant [31].CONCLUSION
A large number of lipid loci have been identified by
meta-analyses of genetic association studies. The
identification of these loci provides novel infor-
mation about the underlying mechanism(s) of lipid
biology, which may eventually lead to novel drug
targets to reduce lipid levels and thereby the risk
of cardiovascular disease. The proportion of thethorized reproduction of this article is prohibited.
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CGenetics and molecular biologygenetic variance explained by these lipid loci is
limited and new studies are ongoing to identify
additional loci. These studies predominantly focus
on the discovery of additional variants by fine
mapping already established loci and aim to detect
rare variants with large effect sizes. Adequately
powered studies in different ethnicities are necess-
ary to establish whether these variants play a
universal role in lipid biology.
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